Clinical Case Series of Gastrointestinal Symptoms in Patients With Novel Coronavirus 2019 Infection

Hamideh Abbaspour kasgari, A. Shabani, H. Fakheri, Parnian Mohammadzadeh
{"title":"Clinical Case Series of Gastrointestinal Symptoms in Patients With Novel Coronavirus 2019 Infection","authors":"Hamideh Abbaspour kasgari, A. Shabani, H. Fakheri, Parnian Mohammadzadeh","doi":"10.18502/pbr.v7i2.7366","DOIUrl":null,"url":null,"abstract":"Background: Various digestive symptoms have been frequently reported in a significant portion of patients infected with the virus since the outbreak of Coronavirus Disease 2019 (COVID-19). Most patients with COVID-19 have a fever accompanied by respiratory signs and symptoms, such as cough and dyspnea. We present 36 cases with a chief complaint of Gastrointestinal (GI) symptoms along with respiratory symptoms. In this study, we aimed at investigating the prevalence and outcomes of COVID-19 patients with digestive symptoms. \nMethods: A variety of observed GI symptoms included nausea and vomiting (72.2%), diarrhea (25%), abdominal pain (19.4%), loss of appetite (14%), and anosmia (14%). The most nonGI symptoms were dyspnea (66.7%), fever (66.7%), dry cough (58.3%), myalgia (52.4%), and others. Six patients (16.6%) were critically ill, 7 (19.4%) were in stable condition, and 23 patients (64%) showed moderate symptoms. Among the patients, 7 (19.5%) needed critical care and were admitted to ICU. Leucopenia, lymphopenia, and elevated acute-phase proteins were other features observed in these patients. The most common antiviral regimen was hydroxychloroquine and oseltamivir. Finally, 32 patients (89%) were discharged, and 4 (11%) died. \nConclusion: This case series study highlights that patients with COVID-19 are prone to GI symptoms along with fever and respiratory symptoms. Patients may even present with digestive symptoms and without any respiratory symptoms. Hence, clinicians should pay more attention to these patients and help diagnose COVID-19 earlier to start prompt treatment before the occurrence of severe disease.","PeriodicalId":6323,"journal":{"name":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/pbr.v7i2.7366","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Various digestive symptoms have been frequently reported in a significant portion of patients infected with the virus since the outbreak of Coronavirus Disease 2019 (COVID-19). Most patients with COVID-19 have a fever accompanied by respiratory signs and symptoms, such as cough and dyspnea. We present 36 cases with a chief complaint of Gastrointestinal (GI) symptoms along with respiratory symptoms. In this study, we aimed at investigating the prevalence and outcomes of COVID-19 patients with digestive symptoms. Methods: A variety of observed GI symptoms included nausea and vomiting (72.2%), diarrhea (25%), abdominal pain (19.4%), loss of appetite (14%), and anosmia (14%). The most nonGI symptoms were dyspnea (66.7%), fever (66.7%), dry cough (58.3%), myalgia (52.4%), and others. Six patients (16.6%) were critically ill, 7 (19.4%) were in stable condition, and 23 patients (64%) showed moderate symptoms. Among the patients, 7 (19.5%) needed critical care and were admitted to ICU. Leucopenia, lymphopenia, and elevated acute-phase proteins were other features observed in these patients. The most common antiviral regimen was hydroxychloroquine and oseltamivir. Finally, 32 patients (89%) were discharged, and 4 (11%) died. Conclusion: This case series study highlights that patients with COVID-19 are prone to GI symptoms along with fever and respiratory symptoms. Patients may even present with digestive symptoms and without any respiratory symptoms. Hence, clinicians should pay more attention to these patients and help diagnose COVID-19 earlier to start prompt treatment before the occurrence of severe disease.
新型冠状病毒2019感染患者胃肠道症状临床病例系列分析
背景:自2019冠状病毒病(COVID-19)爆发以来,相当一部分病毒感染者经常报告各种消化系统症状。大多数COVID-19患者发烧并伴有呼吸道体征和症状,如咳嗽和呼吸困难。我们报告了36例以胃肠道(GI)症状和呼吸道症状为主诉的病例。在这项研究中,我们旨在调查COVID-19患者的患病率和消化系统症状的结局。方法:观察到的各种胃肠道症状包括恶心和呕吐(72.2%)、腹泻(25%)、腹痛(19.4%)、食欲不振(14%)和嗅觉丧失(14%)。非i症状以呼吸困难(66.7%)、发热(66.7%)、干咳(58.3%)、肌痛(52.4%)等为主。危重症6例(16.6%),病情稳定7例(19.4%),中度症状23例(64%)。其中7例(19.5%)需要重症监护并入住ICU。白细胞减少、淋巴细胞减少和急性期蛋白升高是这些患者观察到的其他特征。最常见的抗病毒方案是羟氯喹和奥司他韦。32例(89%)出院,4例(11%)死亡。结论:本病例系列研究强调COVID-19患者易出现胃肠道症状,并伴有发热和呼吸道症状。患者甚至可能出现消化系统症状,而没有任何呼吸道症状。因此,临床医生应加强对这些患者的关注,尽早诊断COVID-19,在病情严重之前及时开始治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信